ClinicalTrials.gg
RecruitingNCT07467239Updated Mar 12, 2026

A Prospective Clinical Investigation of DMFI300 for Treating Nasolabial Folds

An interventional study of DMFI300 and Ellansé-M in Nasolabial Folds, Wrinkles, sponsored by Samyang Biopharmaceuticals Corporation. Recruiting at 1 site in Spain. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-03-12.

Sponsored by Samyang Biopharmaceuticals Corporation · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Mar 2026; still recruiting 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Study summary

This is a prospective, randomized, controlled clinical investigation designed to evaluate the performance and safety of DMFI300 for the treatment of nasolabial folds. 30 adult participants will receive treatment with the investigational device and the comparator device using a split-face design. The study will assess wrinkle severity using validated aesthetic evaluation scales, as well as overall safety.

02

Conditions studied

  • Nasolabial Folds, Wrinkles
03

In context

Lead sponsor

Samyang Biopharmaceuticals Corporation is the lead sponsor of 30 studies on the registry; 6 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Men and women aged 18-70 years.
  • Score of 3 to 4 on the Wrinkle Severity Rating Scale (WSRS) for both nasolabial folds.
  • Willing and able to provide written .
  • Willing to comply with study procedures and follow-up visits.
  • Willing to refrain from other facial cosmetic procedures affecting the nasolabial folds during the study.

Exclusion criteria

Exclusion Criteria:

  • Use of antiplatelet agents, vitamin E, or NSAIDs within 2 weeks before screening or planned use within 2 weeks after treatment.
  • History or presence of bleeding disorders.
  • Participation in another clinical investigation within 1 month prior to screening.
  • Pregnant or breastfeeding women, or women planning pregnancy during the study.
  • Women of not using an effective method of .
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    DMFI300

    Injection of DMFI300

    Device: DMFI300

  • Active comparator
    Ellansé-M

    Injection of Ellansé-M

    Device: Ellansé-M

Interventions

  • DeviceDMFI300

    Injection of DMFI300 for nasolabial folds.

  • DeviceEllansé-M

    Injection of Ellansé-M for nasolabial folds.

06

What researchers measure

Primary outcomes

  1. Change from Baseline in Wrinkle Severity Rating Scale (WSRS) as Assessed by the Evaluating Investigator (EI)

    WSRS is a validated 5-point ordinal scale used to evaluate wrinkle severity (1 = Absent, 2 = Mild, 3 = Moderate, 4 = Severe, 5 = Extreme). Higher scores indicate more severe wrinkles. The blinded EI will assess the change from baseline to Month 12 for each nasolabial fold treated with DMFI300 or Ellansé-M.

    Time frame: Baseline to Month 12

Secondary outcomes

  1. Change from Baseline in Wrinkle Severity Rating Scale (WSRS) Assessed by the Evaluating Investigator (EI) and the Treating Investigator (TI)

    WSRS is a validated 5-point ordinal scale used to evaluate wrinkle severity (1 = Absent, 2 = Mild, 3 = Moderate, 4 = Severe, 5 = Extreme). Changes from baseline will be assessed for each nasolabial fold treated with DMFI300 or Ellansé-M by the EI and TI.

    Time frame: Baseline to Month 1,3,6,9

  2. Global Aesthetic Improvement Scale (GAIS) Assessed by the Treating Investigator (TI) and the Subject

    GAIS is a 5-point global improvement scale (3 = Very Much Improved, 2 = Much Improved, 1 = Improved, 0 = No Change, -1 = Worse). The TI and subject will independently assess GAIS for each nasolabial fold treated with DMFI300 or Ellansé-M.

    Time frame: Month 1,3,6,9,12

  3. Subject Satisfaction With Treatment Using a Five-Point Likert Scale

    Subject satisfaction with treatment will be evaluated using a five-point Likert scale for each nasolabial fold treated with DMFI300 or Ellansé-M.

    Time frame: Month 12

  4. Proportion of Subjects Receiving Touch-up Treatment

    Proportion of subjects who receive additional touch-up treatment at Month 1 after the initial injection if suboptimal improvement is observed.

    Time frame: Month 1

  5. Incidence of Treatment-Related Adverse Events (TRAEs), Adverse Events (AEs), Serious Adverse Events (SAEs), and Device Deficiencies (DDs)

    All TRAEs, AEs, SAEs, and device deficiencies will be recorded and evaluated throughout the clinical investigation.

    Time frame: Baseline through Month 12

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Mar 2026 (actual). Primary completion is estimated for Mar 2027, 12 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 9, 2026
First posted
Mar 12, 2026
StartActual
Mar 2, 2026
Primary completionEst.
Mar 31, 2027
CompletionEst.
May 31, 2027
Last update
Mar 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 12, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07467239
Responsible party
Sponsor
First posted
Mar 12, 2026
Start date
Mar 2, 2026
Primary completion
Mar 31, 2027 (estimated)
Completion
May 31, 2027 (estimated)
Last update
Mar 12, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion